RxDoctor Payments Data

Yoo Jin Chong, MD

Internal Medicine · Carlsbad, CANPI 1831124650

Payments from drug & device makers

$9,319in general payments, 2019–2025

Across 379 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$688
  • Novo Nordisk$677
  • GSK$556
  • Lilly USA, LLC$422
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,14698%
  • Education$1742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,319 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$50,022
Medicare patients
162
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$150,912
FarxigaDapagliflozin Propanediol72$87,503
JardianceEmpagliflozin61$65,427
OzempicSemaglutide33$48,034
ProliaDenosumab28$44,895
TrulicityDulaglutide27$30,990
CreonLipase/Protease/Amylase13$30,590
XareltoRivaroxaban40$26,236
JanuviaSitagliptin Phosphate23$23,823
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,389
MyrbetriqMirabegron30$19,347
JanumetSitagliptin Phos/Metformin Hcl15$13,352
Incruse ElliptaUmeclidinium Bromide26$12,967
Amlodipine-ValsartanAmlodipine Besylate/Valsartan190$9,534
RestasisCyclosporine15$9,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro, Premarin$310$159,030198 claims
AstraZenecaFarxiga$1,761$87,50372 claims
Boehringer IngelheimJardiance, Combivent Respimat$71$72,12775 claims
Novo NordiskOzempic$677$48,03433 claims
AmgenProlia$688$44,89528 claims
AbbVieCreon, Restasis, Synthroid$1,850$44,194100 claims
MerckJanuvia, Janumet$151$37,17438 claims
GSKTrelegy Ellipta, Incruse Ellipta$556$36,35657 claims
Lilly USA, LLCTrulicity$422$30,99027 claims
Johnson & JohnsonXarelto$292$26,23640 claims
Astellas Pharma US IncMyrbetriq$266$19,34730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →